ReviewFrontiers in neurology
Pathological stratification and therapeutic implications for post-stroke depression based on a multidimensional biomarker panel: a narrative review.
Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-stroke depression (PSD) severely impedes neurological recovery and remains difficult to manage using a serotonin-centered treatment paradigm alone. This review summarizes evidence suggesting that PSD arises not from a single neurotransmitter deficiency, but from coupled dysregulation across multiple biological dimensions-including monoamines, neuropeptides, neurotrophic factors, and immune-inflammatory mediators-within and beyond the dorsal raphe nucleus-medial prefrontal cortex (DRN-mPFC) circuit. On this basis, we outline a provisional biomarker-informed phenotypic framework for PSD, including the "low-monoamine phenotype," "high inflammatory burden phenotype", and "neuropeptide-dominant phenotype." We further discuss the potential therapeutic implications of this framework and the possible value of multimodal biomarkers for risk stratification and mechanism-guided management. However, these phenotype-treatment links remain preliminary and should be interpreted according to the strength of available evidence, with PSD-specific clinical evidence prioritized over indirect evidence from major depressive disorder and animal/mechanistic studies. This review therefore provides an evidence-informed conceptual framework for future biomarker-guided research in PSD rather than formal treatment recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.